Mapping value-based healthcare in breast cancer: a scoping review of implemented value programs
Frontiers in Oncology · 18.11.2026 · 16
DOI: 10.3389/fonc.2026.2031005 ↗Kurz gefasst
Scoping Review in der Zeitschrift Frontiers in Oncology, online erschienen am 18.11.2026. Verfasst von Vanessa Chaves Barreto Ferreira de Lima und 6 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer is the most commonly diagnosed cancer in women worldwide, and value-based healthcare (VBHC) offers a framework to improve outcomes per unit of cost across its multidisciplinary care cycle, particularly in early-stage disease, where curative-intent treatment and long-term survivorship place patient-reported outcomes at the center of value. Despite broad endorsement, no review has systematically mapped the adoption of the components of the value agenda in breast cancer services worldwide. This scoping review followed Joanna Briggs Institute methodology and PRISMA-ScR reporting guidelines; PubMed, Embase, and Web of Science were searched in June 2026, supplemented by manual searching of organizational sources. Studies describing the application of VBHC to breast cancer were eligible; conventional economic evaluations and non-implementation studies were excluded. The value-agenda domains and the LEADER framework were used to identify how VBHC is being adopted. We included 12 studies (2014 to 2026), of which 11 described implemented programs, all in high-income settings: the Netherlands (n = 3), the United States (n = 2), Australia (n = 2), Taiwan (n = 1) and Spain (n = 3, two of them multicountry European studies). No programs from Latin America, Africa or South and Southeast Asia were identified. Outcome measurement was the most consistently implemented dimension: 64% of programs referenced the ICHOM standard set, 73% used additional validated instruments, and 73% embedded a culture of value delivery. Economic components were markedly underdeveloped: no program measured real costs using time-driven activity-based costing, and bundled payment was implemented in only two programs (18%). LEADER framework adherence was asymmetric, with accurate outcome data and measurement present in 91% of programs and effective agreements and risk mitigation in only 27% each. A structural gap between a consolidated measurement layer and an underdeveloped financing layer persisted across the twelve years analyzed. Advancing the field requires alignment between PROMs measurement programs with value-based payment initiatives in order to effectively measure the value these strategies deliver to healthcare systems.
Zitieren
APA
Lima, V. C. B. F. D., Messias, A. C. R., Melo, R. C. D., Batista, B. P. D. S. N., Makdissi, F. B. A., Chibana, A. Y., & Etges, A. P. B. D. S. (2026). Mapping value-based healthcare in breast cancer: a scoping review of implemented value programs. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2031005
Vancouver
Lima VCBFD, Messias ACR, Melo RCD, Batista BPDSN, Makdissi FBA, Chibana AY, et al. Mapping value-based healthcare in breast cancer: a scoping review of implemented value programs. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2031005
BibTeX
@article{Lima2026,
author = {Lima, Vanessa Chaves Barreto Ferreira de and Messias, Anna Carolina Riul and Melo, Roberta Crevelario de and Batista, Bernardo Pinheiro de Senna Nogueira and Makdissi, Fabiana Baroni Alves and Chibana, Aline Yuri and Etges, Ana Paula Beck da Silva},
title = {Mapping value-based healthcare in breast cancer: a scoping review of implemented value programs},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.2031005}
}
EUVIMED